Chemoimmunotherapeutic effect of cyclophosphamide on the highly metastatic MAT 13762 tumor.
We have observed that cyclophosphamide (CY) treatment of 13762 mammary adenocarcinoma tumor-bearing rats was found to cause tumor regression. Tumor-bearing animals cured with three low doses of CY were partially immune against IV and SC challenge with a high dose of 13762 cells. This immune protection mechanism in CY-cured animals appears to be a T (Ig-) cell-mediated response. Irradiated rats reconstituted with CY-cured animal spleen cells were also partially protected against IV and SC challenge with 13762 cells, whereas irradiated rats reconstituted with CY-control animal spleen cells were not. In vitro primary and secondary cell-mediated cytotoxic activity of CY-cured spleen cells against target 13762 cells was low. The possible relevance of this tumor-model study is in the understanding of CY-induced tumor immune response and its role in preventing metastases or perhaps recurrent tumor growth.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D005260:Female; D007116:Immunization, Passive; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000556:secondary; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000276:immunology; D051381:Rats; D011916:Rats, Inbred F344
D003520:Cyclophosphamide